Novasep Invests €6 Million into Chasse-sur-Rhône Site

Novasep (Lyon, France) has announced a €6 million investment of its Chasse-sur-Rhône site, in Lyon, France. This investment will increase and modernize its manufacturing capabilities to support new generation active pharmaceutical ingredients (APIs), in areas such as oncology, central nervous system (CNS), and infectious diseases.

Continuous, or flow chemistry, is a growing area of importance in API manufacturing, offering advantages such as improved productivity, reduced energy and solvent consumption, better reaction control, increased process safety, and reduced exposure for personnel over traditional batch chemistry.

Novasep has invested heavily into flow chemistry since the establishment of a research platform at the Chasse-sur-Rhône site in 2013. This latest investment sees the installation of a cGMP flow reactor, and strengthens the site’s ability to develop methods for efficient process development under continuous flow conditions.

“The addition of a cGMP flow capability at manufacturing scale, a technology which Novasep has been working on for several years in R&D, is an important step forward to strengthen our competitiveness in the active pharmaceutical ingredients market,” said Catherine Vindevoghel, Site Director of Chasse-sur-Rhône.

“We are proud of this investment, which will increase employment opportunities in France whilst improving responsiveness and reinforcing manufacturing capacities for essential therapeutic drugs for our customers, and ultimately for patients,” continued Vindevoghel.

In parallel, Novasep continues to reinforce its capabilities on the site for low to medium volume APIs, in response to increased customer demand (through the debottlenecking of drying and purification capacities, and the addition of a new clean room). These investments will enable Novasep to accommodate customers’ growing needs for outsourced API manufacturing services, increasing flexibility, reinforcing state‑of‑the‑art technologies, and strengthening its competitiveness.

The investment project was also selected and supported by the French government as part of the “France Relance” recovery plan. The programme rewards innovative and promising industrial investments in France, with the aim of reinforcing production capabilities of APIs for essential therapies, increasing economic growth and boosting employment.

For more information, please visit: www.novasep.com